Hipertensión arterial y riñón

  1. de la Fuente, G. de Arriba
  2. del Valle, K.M. Pérez
  3. Gaitán Tocora, D.G.
  4. Puyol, D. Rodríguez
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2019

Título del ejemplar: Enfermedades nefrourinarias (III) Hipertensión y enfermedades vasculares renales

Serie: 12

Número: 81

Páginas: 4759-4764

Tipo: Artículo

DOI: HTTPS://DOI.ORG/10.1016/J.MED.2019.06.001 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

Resumen Los determinantes de la presión arterial son el gasto cardíaco y las resistencias periféricas. Aunque los mecanismos por los que el riñón interviene en el control de la presión arterial son complejos, es bien conocido el hecho de que actúa sobre ambos. Así, puede modificar el gasto cardíaco a través de su capacidad de regular la volemia extracelular, modulando la eliminación urinaria de sodio y agua. Por otro lado, el riñón influye en las resistencias periféricas, gracias a la síntesis de sustancias vasoconstrictoras y vasodilatadoras que modifican tanto el tono como la estructura de la pared vascular. En esta actualización se realizará una revisión de los principales mecanismos renales que intervienen en el control de la presión arterial, haciendo hincapié en aquellos que tienen más trascendencia en las enfermedades asociadas a hipertensión arterial. El conocer estos mecanismos también nos ayudará a entender la forma de acción de los hipotensores. .

Referencias bibliográficas

  • Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL. Role of nitric oxide in the cardiovascular and renal systems. Int J Mol Sci. 2018; 19(9):1-23.
  • Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J. Endovascular ultrasound renal denervation to treat hypertension (RA-DIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham controlled trial. Lancet. 2018 ;391(10137):2335-45.
  • Barrio V, De Arriba G, López-Novoa JM, Rodríguez-Puyol D. Atrial natriuretic peptide inhibits glomerular contraction induced by angiotensin II and platelet activating factor. Eur J Pharmacol. 1987;135(1):93-6.
  • Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high, middle, and low income countries. JAMA. 2013;310(9):959-68.
  • De Arriba G, Barrio V, Olivera A, Rodríguez-Puyol D, López-Novoa JM. Atrial natriuretic peptide inhibits angiotensin II : induced contraction of isolated glomeruli and cultured glomerular mesangial cells of rats: the role of calcium. J Lab Clin Med. 1988;111(4):466-74.
  • DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633-41.
  • Drawz PE, Alper AB, Anderson AH, Brecklin CS, Charleston J, Chen J. Masked hypertension and elevated nighttime blood pressure in CKD: prevalence and association with target organ damage. Clin J Am Soc Nephrol. 2016;11(4):642-52.
  • Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34(13):951-61.
  • Evans RG, Bie P. Role of the kidney in the pathogenesis of hypertension: time for a neoGuytonian paradigm or a paradigm shift? Am J Physiol Regul Integr Comp Physiol. 2016;310(3):R217-29.
  • Guyton AC, Coleman TG, Cowley AV, Jr., Scheel KW, Manning RD, Jr., Norman RA, Jr. Arterial pressure regulation. Overriding dominance of the kidneys in long term regulation and in hypertension. Am J Med. 1972;52(5):584-94.
  • Hall JE, Brands MW, Shek EW. Central role of the kidney and abnormal fluid volume control in hypertension. J Hum Hypertens. 1996;10(10):633-9.
  • Hall JE, Guyton AC, Brands MW. Pressure volume regulation in hypertension. Kidney Int Suppl. 1996;55:S35-41.
  • Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32(5):659-68.
  • Horowitz B, Miskulin D, Zager P. Epidemiology of hypertension in CKD. Adv Chronic Kidney Dis. 2015;22(2):88-95.
  • Ichikawi I, Harris RC. Angiotensin actions in the kidney: renewed insight into the old hormone. Kidney Int. 1991;40(4):583-96.
  • Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof of concept randomised trial. Lancet. 2018;391(10137):2346-55.
  • Kurtz TW, Dominiczak AF, DiCarlo SE, Pravenec M, Morris RC, Jr. Molecular based mechanisms of Mendelian forms of salt-dependent hy-pertension: questioning the prevailing theory. Hypertension. 2015;65(5): 932-41.
  • Lahera V, Salom MG, Miranda-Guardiola F, Moncada S, Romero JC. Effects of NG-nitro L-arginine methyl ester on renal function and blood pressure. Am J Physiol. 1991;261(6 Pt 2):F1033-7.
  • Liang J, Le TH, Edwards DRV, Tayo BO, Gaulton KJ, Smith JA. Single trait and multitrait genome wide association analyses identify novel loci for blood pressure in African ancestry populations. PLoS Ge-net. 2017;13(5):e1006728.
  • Llorens S, Jordan J, Nava E. The nitric oxide pathway in the cardiovascular system. J Physiol Biochem. 2002;58(3):179-88.
  • Loperena R, Harrison DG. Oxidative stress and hypertensive diseases. Med Clin North Am. 2017;101(1):169-93
  • Malhotra R, Nguyen HA, Benavente O, Mete M, Howard BV, Mant J. Association Between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis. JAMA Intern Med. 2017;177(10):1498-505.
  • Mange KC, Cizman B, Joffe M, Feldman HI. Arterial hypertension and renal allograft survival. JAMA. 2000;283(5):633-8.
  • Marín R, Goicoechea MA, Gorostidi M, Cases A, Díez J, Escolar G. Guía de la Sociedad Española de Nefrología sobre riñón y enfermedad cardiovascular. Versión abreviada. Nefrología. 2006;26(1):31-44.
  • Morris RC, Jr., Schmidlin O, Sebastian A, Tanaka M, Kurtz TW. Vasodys function that involves renal vasodysfunction, not abnormally increased renal retention of sodium, accounts for the initiation of salt : induced hypertension. Circulation. 2016;133(9):881-93.
  • Muñoz-Durango N, Fuentes CA, Castillo AE, González-Gómez LM, Vecchiola A, Fardella CE. Role of the Renin Angiotensin Aldosterone System beyond Blood Pressure Regulation: Molecular and Cellular Mechanisms Involved in End-Organ Damage during Arterial Hyperten-sion. Int J Mol Sci. 2016;17(7):1-17.
  • Pavlov TS, Staruschenko A. Involvement of ENaC in the development of salt : sensitive hypertension. Am J Physiol Renal Physiol. 2017;313(2):F135-40.
  • Romero JC, Knox FG. Mechanisms underlying pressure related natriuresis: the role of the reninangiotensin and prostaglandin systems. State of the art lecture. Hypertension. 1988;11(6 Pt 2):724-38.
  • Rossier BC, Baker ME, Studer RA. Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev. 2015;95(1):297-340
  • Rossier BC, Bochud M, Devuyst O. The hypertension pandemic: an evolutionary perspective. Physiology (Bethesda). 2017;32(2):112-25
  • Satoh N, Nakamura M, Suzuki A, Tsukada H, Horita S, Suzuki M. Effects of nitric oxide on renal proximal tubular Na(+) transport. Biomed Res Int. 2017;2017:6871081.
  • Sinha N, Dabla PK. Oxidative stress and antioxidants in hypertension : a current review. Curr Hypertens Rev. 2015;11(2):132-42.
  • Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2): 220-6.
  • Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA. Catheter based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham controlled, proof of concept trial. Lancet. 2017;390(10108):2160-70.
  • Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-104.
  • Xu M, Lu YP, Hasan AA, Hocher B. Plasma ET-1 Concentrations are elevated in patients with hypertension : meta-analysis of clinical studies. Kidney Blood Press Res. 2017;42(2):304-13.
Fuente de los datos: Dialnet